How Can I Beat the S&P 500? What the Evidence Says
The honest answer to the most asked question in investing: how many people beat the index, why it is so hard, why investors trail even their own funds, and how daily market context fits in.
StocksInsight
RMD Stock vs the S&P 500: Returns, Risk and Crash History
ResMed Inc., healthcare (market value $33.7 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Data as of Oct 30, 2026.
What changed since Oct 26
Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.
47% Buy ratings (was 44%)17 analysts covering (was 18)−5.9% 1‑year return through Oct 30 (was −18.4%)
Key takeaways
- RMD returned −8.5% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
- Its 5-year Sharpe ratio was −0.03 against 0.58 for the S&P 500.
- Its deepest crisis drawdown was −43.8% in the global financial crisis (2007–09) (S&P 500: −56.5%).
- Five‑year volatility was 31.1% and beta 0.77.
- 17 analysts rated it in the past year; 47% of their latest calls were Buy.
- RMD beat earnings estimates in 11 of its last 12 reports; the stock moved 5.9% on average, up or down, around each report.
What do the best‑ranked analysts on RMD say now? See it in Exent Gems →
In this article
- Did RMD beat the S&P 500?
- What Wall Street analysts say about RMD
- RMD returns by year vs the S&P 500
- RMD risk-adjusted returns: Sharpe, Sortino and volatility
- How RMD behaved in past crashes
- What moves with RMD, and what doesn’t
- Latest RMD upgrades, downgrades and price‑target changes
- Do analysts get RMD right?
- How RMD moves after earnings
- Where RMD’s revenue comes from
- Members of Congress who traded RMD
- Are RMD insiders buying or selling?
- How much of RMD is sold short?
- How many institutions own RMD?
- Is RMD diluting shareholders?
- RMD financial health scores
- What RMD talks about on earnings calls
- Which ETFs hold RMD?
- The right benchmark for RMD
- Other healthcare stocks
- Data and methodology
Did RMD beat the S&P 500?
Over the 5 years to Oct 30, 2026, ResMed Inc. (RMD) returned −8.5% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 84.4 percentage points, or −1.8% a year against +12.0%.
| Period | RMD | S&P 500 | RMD per year | S&P 500 per year | Result |
|---|---|---|---|---|---|
| 1 year | −5.9% | +12.0% | −5.9% | +12.0% | Lagged |
| 3 years | +67.7% | +87.4% | +18.8% | +23.3% | Lagged |
| 5 years | −8.5% | +75.9% | −1.8% | +12.0% | Lagged |
| 10 years | +329.7% | +316.3% | +15.7% | +15.3% | Beat |
- 1 year
- RMD
- −5.9%
- S&P 500
- +12.0%
- RMD per year
- −5.9%
- S&P 500 per year
- +12.0%
- Result
- Lagged
- 3 years
- RMD
- +67.7%
- S&P 500
- +87.4%
- RMD per year
- +18.8%
- S&P 500 per year
- +23.3%
- Result
- Lagged
- 5 years
- RMD
- −8.5%
- S&P 500
- +75.9%
- RMD per year
- −1.8%
- S&P 500 per year
- +12.0%
- Result
- Lagged
- 10 years
- RMD
- +329.7%
- S&P 500
- +316.3%
- RMD per year
- +15.7%
- S&P 500 per year
- +15.3%
- Result
- Beat
Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.
RMD is in the S&P 500 (members as of Oct 20, 2026); the list shows every member’s return against the index.
What Wall Street analysts say about RMD
In the 12 months to 30 days ago, 17 analysts published 152 ratings on RMD. Their latest calls were 47% Buy, 53% Hold and 0% Sell. 2 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.
The consensus 12‑month price target was $296.87 (range $230.00–$345.00), +27.4% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?
| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
|---|---|---|---|
| Adam Maeder | Piper Sandler | 4.7★ | 46.7% |
| Anthony Petrone | Mizuho Securities | 4.7★ | 44.4% |
Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on RMD are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.
The average analyst’s target is reached about 53.1% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.
RMD returns by year vs the S&P 500
RMD beat the S&P 500 in 5 of the 9 full calendar years shown.
| Year | RMD | S&P 500 | Difference |
|---|---|---|---|
| 2026 (to Oct 30, 2026) | −3.8% | +11.7% | −15.5% |
| 2025 | +6.3% | +17.7% | −11.4% |
| 2024 | +34.2% | +24.9% | +9.3% |
| 2023 | −16.5% | +26.2% | −42.7% |
| 2022 | −19.5% | −18.2% | −1.3% |
| 2021 | +23.4% | +28.7% | −5.3% |
| 2020 | +38.3% | +18.3% | +20.0% |
| 2019 | +37.8% | +31.2% | +6.6% |
| 2018 | +36.4% | −4.6% | +41.0% |
| 2017 | +39.1% | +21.7% | +17.4% |
RMD risk-adjusted returns: Sharpe, Sortino and volatility
Over 5 years, RMD had a Sharpe ratio of −0.03 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 29.8% and its beta 0.77: it tended to move about 0.8× as much as the market.
| Metric | RMD | S&P 500 |
|---|---|---|
| Annual return | −1.8% | +12.0% |
| Volatility (annualized) | 29.8% | 15.5% |
| Sharpe ratio | −0.03 | 0.58 |
| Sortino ratio | −0.04 | 0.91 |
| Max drawdown (month-end) | −45.4% | −23.9% |
| Beta to the S&P 500 | 0.77 | 1.00 |
Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.
How RMD behaved in past crashes
RMD’s deepest fall in the crises below was −43.8% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.
| Crisis | RMD | S&P 500 | Loss on $100,000 |
|---|---|---|---|
| Global financial crisis (2007–09) | −43.8% | −56.5% | −$43,800 |
| 2018 trade-war selloff | −15.1% | −20.2% | −$15,140 |
| COVID crash (Feb–Mar 2020) | −35.3% | −34.1% | −$35,260 |
| 2022 inflation bear market | −26.8% | −25.4% | −$26,790 |
| 2025 tariff selloff | −13.6% | −19.0% | −$13,560 |
| Window | RMD max drawdown |
|---|---|
| Last 1 year | −34.6% |
| Last 3 years | −40.1% |
| Last 5 years | −54.0% |
| Last 10 years | −54.7% |
Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.
What moves with RMD, and what doesn’t
Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, RMD’s correlation with the S&P 500 was 0.40, with the Nasdaq‑100 0.25, with long Treasuries (TLT) 0.45 and with gold (GLD) 0.34.
Adding a 5% RMD position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.3%.
| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
|---|---|---|---|
| DELL | −0.13 | MCO | 0.54 |
| INTC | −0.10 | PNC | 0.50 |
| CRWD | −0.06 | SYK | 0.50 |
| CSCO | −0.02 | SBUX | 0.49 |
| LLY | −0.01 | HCA | 0.49 |
Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.
Latest RMD upgrades, downgrades and price‑target changes
| Date | Rating and target | Analyst |
|---|---|---|
| Oct 30 | Target raised Hold | Adam Maeder |
| Oct 30 | Target raised Buy | Anthony Petrone |
| Oct 13 | Target raised Buy | Anthony Petrone |
| Sep 15 | Upgrade Hold → Buy | Craig Wong-Pan |
| Sep 10 | Target raised Hold | Laura Sutcliffe |
| Aug 31 | Target raised Buy | Brett Fishbin |
Named analysts’ rating and price‑target changes on RMD in the 5 weeks to Oct 4, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.
Do analysts get RMD right?
Of the 214 analyst price targets on RMD set from 2019 until a year ago, 68.7% were reached within 12 months (data to Oct 20, 2026), 0.1 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 68 days. The median target sat 11.1% above the share price on the day it was set.
Where analysts said RMD would be by now: a year ago, 6 analysts had a price target on RMD, and the median of their latest targets was $301.50. On Oct 20, 2026 RMD closed at $245.54, 18.6% below it.
68.7%of targets reached within 12 monthsMedian stock: 68.6%
68 daysmedian time to reach a target
−18.6%price now vs the median target set a year ago
| After | Calls | Move on the call | 3 months vs S&P 500 |
|---|---|---|---|
| Upgrades of RMD | 27 | +1.8% | +4.9% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |
| Downgrades of RMD | 26 | −3.8% | +0.6% |
| Downgrades, all stocks | 10,700 | −3.0% | −1.6% |
The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on RMD through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?
How RMD moves after earnings
RMD beat the consensus earnings‑per‑share estimate in 11 of its last 12 quarterly reports, through the one on Aug 6, 2026, and the revenue estimate in 11 of 12. From the close before each report to the close after it, the stock moved 5.9% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 7 of the 12 reports. In 5 of the 11 beats the stock still fell.
11/12earnings beats
±5.9%average move per report
7/12reports followed by a rise
| Report | EPS vs estimate | Revenue vs estimate | Stock move |
|---|---|---|---|
| Aug 6, 2026 | $2.95 vs $2.89 | +0.2% | −5.4% |
| Apr 30, 2026 | $2.86 vs $2.80 | +0.8% | −3.3% |
| Jan 29, 2026 | $2.81 vs $2.74 | +1.6% | +0.2% |
| Oct 30, 2025 | $2.55 vs $2.51 | +0.2% | −2.7% |
| Jul 31, 2025 | $2.55 vs $2.46 | +1.3% | +0.6% |
| Apr 23, 2025 | $2.37 vs $2.38 | +0.3% | +10.3% |
| Jan 30, 2025 | $2.43 vs $2.32 | +1.2% | −6.6% |
| Oct 24, 2024 | $2.20 vs $2.04 | +3.3% | +7.9% |
Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings
Where RMD’s revenue comes from
In fiscal 2024 (the year to Jun 30, 2024), RMD’s largest reported region was U [S], with 63.6% of its $4.7 billion revenue. By region: U [S] 63.6%; Global 36.4%.
By business, the largest segment was Sleep And Respiratory, with 87.5% of $4.7 billion revenue (+10.1% on the year before).
| Segment | Revenue | Share | Growth |
|---|---|---|---|
| Sleep And Respiratory | $4.1 billion | 87.5% | +10.1% |
| Software As Service | $584.1 million | 12.5% | +17.3% |
From RMD’s annual filings; segment growth compares fiscal 2024 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?
Members of Congress who traded RMD
As of Oct 20, 2026, 9 members of Congress had disclosed 36 trades in RMD (17 buys and 19 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated May 1, 2026.
| Trade date | Member | Type | Amount |
|---|---|---|---|
| May 1, 2026 | Ro Khanna | Buy | $1,001–$15,000 |
| Apr 13, 2026 | Ro Khanna | Buy | $1,001–$15,000 |
| Mar 27, 2026 | Alan Armstrong | Buy | $1,001–$15,000 |
| Jan 29, 2026 | Ro Khanna | Sale | $1,001–$15,000 |
| Jun 4, 2025 | Kelly Louise Morrison | Sale | $1,001–$15,000 |
| Apr 28, 2025 | Kelly Louise Morrison | Sale | $1,001–$15,000 |
| Jan 13, 2025 | Rob Bresnahan | Sale | $1,001–$15,000 |
| Nov 15, 2024 | Ro Khanna | Buy | $1,001–$15,000 |
| May 3, 2024 | Thomas Tuberville | Sale | $1,001–$15,000 |
| Oct 31, 2023 | Ro Khanna | Buy | $1,001–$15,000 |
Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades
One trade in RMD disclosed in the last 30 days is in Exent Radar.
Are RMD insiders buying or selling?
In the 12 months to Oct 20, 2026, RMD insiders made no open‑market purchases and 22 sales worth $22.3 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Aug 17, 2016.
After the 1 insider purchase of $10,000 or more since 2012, RMD lagged the S&P 500 by an average of 5.1 percentage points over the next 12 months; none of them was followed by a beat (a small sample). Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.
| Date | Insider | Role | Value |
|---|---|---|---|
| Aug 17, 2016 | Taylor Ronald R | Director | $171,926 |
| Aug 21, 2006 | Sulpizio Richard | Director | $424,500 |
| May 20, 2002 | Quinn Michael A | Director | $1.5 million |
The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?
How much of RMD is sold short?
As of the Sep 30, 2026 settlement date, 9.18% of RMD’s float was sold short: 12.8 million shares, or 9.9 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 6.43%. The median across the 997 US stocks Exent tracks was 4.77%, so RMD is more heavily shorted than most.
From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks
How many institutions own RMD?
At the end of Q2 2026 (Jun 30, 2026), 921 institutions reported holding RMD in 13F filings, down 51 from the quarter before and down from 963 a year earlier. Their reported holdings add up to 69.9% of RMD’s shares. In the quarter 399 institutions added to their positions and 368 cut them.
92113F holders
92new positions
145positions closed
69.9%of shares held by 13F filers
Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling
Is RMD diluting shareholders?
RMD’s diluted share count fell 1.0% over the five fiscal years to fiscal 2026 and fell 1.6% in fiscal 2026 alone. Each share now owns a larger slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.
Stock‑based compensation was $104.3 million in fiscal 2026, 1.8% of revenue. RMD spent $700.0 million buying back shares, a buyback yield of 2.01% of its market value; stock pay equaled 14.9% of the buybacks.
−1.6%share count, 1 year
−1.0%share count, 5 years
1.8%stock pay as % of revenue
2.01%buyback yield
Weighted‑average diluted shares from RMD’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained
RMD financial health scores
In Exent’s Oct 20, 2026 snapshot, RMD’s Altman Z‑score was 11.36, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was 6 out of 9; 62% of scored stocks reach 6 or more.
11.36Altman Z‑score: safe zone
6/9Piotroski F‑score
The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?
What RMD talks about on earnings calls
On its latest earnings call (Aug 6, 2026), RMD’s executives and analysts mentioned AI 5 times, against 2 on the call before (Apr 30, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was tariffs (3).
| Mentions | Aug ’26 | Apr ’26 | Jan ’26 | Oct ’25 |
|---|---|---|---|---|
| AI | 5 | 2 | 5 | 11 |
| AI agents | 0 | 0 | 0 | 0 |
| Data centers | 0 | 0 | 0 | 0 |
| Tariffs | 3 | 0 | 1 | 2 |
| China | 3 | 4 | 4 | 2 |
| Recession | 0 | 0 | 0 | 0 |
- AI
- Aug ’26
- 5
- Apr ’26
- 2
- Jan ’26
- 5
- Oct ’25
- 11
- AI agents
- Aug ’26
- 0
- Apr ’26
- 0
- Jan ’26
- 0
- Oct ’25
- 0
- Data centers
- Aug ’26
- 0
- Apr ’26
- 0
- Jan ’26
- 0
- Oct ’25
- 0
- Tariffs
- Aug ’26
- 3
- Apr ’26
- 0
- Jan ’26
- 1
- Oct ’25
- 2
- China
- Aug ’26
- 3
- Apr ’26
- 4
- Jan ’26
- 4
- Oct ’25
- 2
- Recession
- Aug ’26
- 0
- Apr ’26
- 0
- Jan ’26
- 0
- Oct ’25
- 0
Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. Which companies talk most about AI?
Which ETFs hold RMD?
As of Oct 20, 2026, 61 of the 304 ETFs Exent tracks held RMD. Its largest weight is in RDVY (First Trust Rising Dividend Achievers ETF), at 1.55% of the fund.
| ETF | Fund | Weight of RMD |
|---|---|---|
| RDVY | First Trust Rising Dividend Achievers ETF | 1.55% |
| RDVI | FT Vest Rising Dividend Achievers Target Income ETF | 1.55% |
| FXH | First Trust Health Care AlphaDEX Fund | 1.42% |
| VOT | Vanguard Mid-Cap Growth Index Fund | 0.75% |
| DSTL | Distillate U.S. Fundamental Stability & Value ETF | 0.73% |
| XLV | State Street Health Care Select Sector SPDR ETF | 0.54% |
| VHT | Vanguard Health Care Index Fund ETF Shares | 0.45% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.40% |
Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?
The right benchmark for RMD
Exent matches every holding to the index with the most similar risk. For RMD that is SPY (the S&P 500). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.
Other healthcare stocks
| Ticker | Name | 5‑year return | Volatility (5y) |
|---|---|---|---|
| LLY | Eli Lilly and Company | +482.3% | 32.6% |
| JNJ | Johnson & Johnson | +92.9% | 16.8% |
| ABBV | AbbVie Inc. | +207.1% | 23.5% |
| UNH | UnitedHealth Group Incorporated | −3.3% | 32.7% |
| MRK | Merck & Co., Inc. | +97.8% | 23.6% |
| AMGN | Amgen Inc. | +163.1% | 24.8% |
| TMO | Thermo Fisher Scientific Inc. | +11.7% | 27.0% |
| GILD | Gilead Sciences, Inc. | +214.3% | 24.8% |
Data and methodology
Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.
Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
Check RMD with Exent Gems
Wall Street’s average RMD price target is 27.4% above the latest share price. See what the best‑ranked analysts on RMD say now in Exent Gems.
- Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
- Gems shows who the top‑ranked analysts covering RMD are, their live calls and the median target of only the top‑rated analysts.
- Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.
Frequently asked questions
Yes. RMD returned +329.7% (+15.7% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.
Yes. As of Oct 20, 2026, RMD (ResMed Inc.) is one of the 503 stocks in the S&P 500.
RMD fell −43.8% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.
RMD fell −35.3% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.
RMD fell −26.8% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.
Over the 5 years to Oct 30, 2026, RMD’s Sharpe ratio was −0.03 and its Sortino ratio −0.04, versus 0.58 and 0.91 for the S&P 500.
RMD’s 5‑year annualized volatility was 31.1%, higher than the S&P 500’s 17.0%, with a beta of 0.77.
Among large US stocks, the lowest correlations with RMD over the last 60 months were DELL (−0.13), INTC (−0.10), CRWD (−0.06). Its correlation with long Treasuries (TLT) was 0.45 and with gold (GLD) 0.34.
RMD beat the consensus earnings-per-share estimate in 11 of its last 12 quarterly reports through Aug 6, 2026, and the revenue estimate in 11 of 12. The stock moved 5.9% on average, up or down, from the close before each report to the close after it.
Yes. As of Oct 20, 2026, 9 members of Congress had disclosed 36 trades in RMD (17 buys and 19 sales) in STOCK Act disclosures filed with the House and Senate.
As of the Sep 30, 2026 settlement date, 9.18% of RMD’s float was sold short (12.8 million shares, 9.9 days to cover), according to FINRA short-interest reports. A year earlier it was 6.43%.
No. RMD’s diluted share count fell 1.0% over the five fiscal years to fiscal 2026 and fell 1.6% in the latest year. Stock-based compensation was 1.8% of revenue, and buybacks totaled $700.0 million.
What do the best‑ranked analysts say on RMD now?
Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on RMD are, their latest calls and the stocks where several of them agree.
See this week’s GemsLimited offer$1.95 for full access· full access
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.